Cargando…

Pharmaceutical security for Canada

Detalles Bibliográficos
Autores principales:	Lee, Shoo K., Mahl, Sukhy K., Rowe, Brian H., Lexchin, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2022
Materias:	Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528533/ https://www.ncbi.nlm.nih.gov/pubmed/35995443 http://dx.doi.org/10.1503/cmaj.220324

Ejemplares similares

Sécurité d’approvisionnement pharmaceutique au Canada
por: Lee, Shoo K., et al.
Publicado: (2022)

Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
por: Lee, Shoo K., et al.
Publicado: (2023)

Increased Private Healthcare for Canada: Is That the Right Solution?
por: Lee, Shoo K., et al.
Publicado: (2021)

Canada's System of Liability Coverage in the Event of Medical Harm: Is It Time for No-Fault Reform?
por: Lee, Shoo K., et al.
Publicado: (2021)

The Induced Productivity Decline Hypothesis: More Physicians, Higher Compensation and Fewer Services
por: Lee, Shoo K., et al.
Publicado: (2021)

Marketing before patenting: implications for price controls in Canada
por: Lexchin, Joel
Publicado: (2010)

Canada and the pharmaceutical industry in the time of COVID-19
por: Lexchin, Joel
Publicado: (2023)

'Linkage' pharmaceutical evergreening in Canada and Australia
por: Faunce, Thomas A, et al.
Publicado: (2007)

How well do Canadian media outlets convey medical treatment information?: Initial findings from a year and a half of media monitoring by Media Doctor Canada
por: Cassels, Alan, et al.
Publicado: (2008)

Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada
por: Lexchin, Joel
Publicado: (2023)

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis
por: Lexchin, Joel
Publicado: (2018)

Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada
por: Lexchin, Joel
Publicado: (2021)

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
por: Lexchin, Joel, et al.
Publicado: (2014)

A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada
por: Morgan, Steven G., et al.
Publicado: (2016)

Improving access to medicines and beyond: the national volume-based procurement policy in China
por: Zhu, Zheng, et al.
Publicado: (2023)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Models for financing the regulation of pharmaceutical promotion
por: Lexchin, Joel
Publicado: (2012)

Global health security and the health-security nexus: principles, politics and praxis
por: McCoy, David, et al.
Publicado: (2023)

The Pharmaceutical Industry and the Canadian Government: Folie à Deux
por: Lexchin, Joel
Publicado: (2017)

Making pharmaceutical research and regulation work for women
por: Ravindran, TK Sundari, et al.
Publicado: (2020)

Cuba y seguridad sanitaria mundial: Cuba’s role in global health security
por: Wenham, Clare, et al.
Publicado: (2020)

Evaluation of pharmaceutical industry-led access programmes: a standardised framework
por: Rockers, Peter C, et al.
Publicado: (2019)

Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
por: Gaudette, Étienne, et al.
Publicado: (2023)

Health Canada's Proposal to Accelerate New Drug Reviews
por: Lexchin, Joel
Publicado: (2020)

The value proposition of the Global Health Security Index
por: Ravi, Sanjana J, et al.
Publicado: (2020)

Ensuring equitable access to cancer care for Black patients in Canada
por: Ezeife, Doreen A., et al.
Publicado: (2022)

Time to Marketing of Generic Drugs After Patent Expiration in Canada
por: Lexchin, Joel
Publicado: (2021)

Reconceptualising health security in post-COVID-19 world
por: Malik, Sadia Mariam, et al.
Publicado: (2021)

Non-pharmaceutical interventions during the roll out of covid-19 vaccines
por: Zhang, Yi, et al.
Publicado: (2021)

Canada and access to medicines in developing countries: intellectual property rights first
por: Lexchin, Joel
Publicado: (2013)

It’s Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada"
por: Lexchin, Joel
Publicado: (2020)

Integrating research into clinical practice: challenges and solutions for Canada
por: Lamontagne, François, et al.
Publicado: (2021)

Medicines Information and the Regulation of the Promotion of Pharmaceuticals
por: Leonardo Alves, Teresa, et al.
Publicado: (2018)

After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada
por: Lexchin, Joel
Publicado: (2022)

Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
por: Lexchin, Joel
Publicado: (2011)

Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2020)

Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021)

Excess mortality, COVID-19 and health care systems in Canada
por: McGrail, Kimberlyn
Publicado: (2022)

Assessing the need for Black mentorship within residency training in Canada
por: Egbedeyi, Onaope, et al.
Publicado: (2022)

The potential benefits of a national vaccine registry for Canada
por: Gorfinkel, Iris S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rne0goh5s8anpqjcbsscqmc8i0